You are seeing these quotes based on previous browsing related to sectors such as
| Latest | Forecast | |
|---|---|---|
| Div Yield | 0.0% | n/a |
| Div Cover | n/a | n/a |
| Op Mrgn | 0.0% | n/a |
| ROCE | 0.0% |
| Latest | Forecast | |
|---|---|---|
| P/E | -2.7 | n/a |
| PEG | 0.0 | n/a |
| Price / Revenue | 0.0 | n/a |
| Price / Book value | 1.7 |
| Latest | Forecast | |
|---|---|---|
| Revenue | n/a | n/a |
| PBT | 0.0% | n/a |
| EPS | 0.0% | n/a |
| DPS | n/a | n/a |
| Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2020-12-31 | n/a | -0.51 | -1.89p | 0.0 | 0.0 | n/a | n/a | 0.0% |
| 2021-12-31 | n/a | -2.53 | -6.02p | -4.9 | 0.0 | n/a | n/a | 0.0% |
| Michael Kauffman promoted to BiVictriX board chair Sharecast News | 06 Jan |
|---|---|
| BiVictriX identifies development lead for potential cancer drug Sharecast News | 07 Dec |
| BiVictriX upbeat on recent pipeline progress Sharecast News | 11 Jul |
| Appointment of Alex Hughes as CFO | 01-Mar-23 15:46 |
|---|---|
| BiVictriX reports positive BVX001 preclinical data | 31-Jan-23 14:56 |
| Holding(s) in Company | 24-Jan-23 23:59 |
| Holding(s) in Company | 19-Jan-23 19:25 |
| Holding(s) in Company | 19-Jan-23 14:23 |